Compare Citius Pharmaceuticals Inc (CTXR) vs Futu Holdings Ltd (FUTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Futu Holdings Ltd — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while Futu Holdings Ltd trades at $105.19 (market cap $14.74B). The key difference: Futu Holdings Ltd is far larger — about 736.6× Citius Pharmaceuticals Inc's market cap, and Futu Holdings Ltd pays a 2.47% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | FUTU | |
|---|---|---|
Market Cap | $20.01M | $14.74B |
Sector | Health | Financials |
52-Week High | $1.82 | $199.04 |
52-Week Low | $0.48 | $89.76 |
Enterprise Value | $16.23M | $14.59B |
Dividend Yield | — | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
FUTU trades at $105.41, down 3.03% today, amid a securities class action filing alleging regulatory compliance failures. The stock shows strong fundamentals with a P/E of 11.63 and net income margin of 41.83%, supported by robust revenue growth from $13.6B in 2024 to $22.85B in 2025. Technical indicators are bullish on moving averages, with key support at $103 and resistance at $110.
The outlook is mixed: strong profitability and analyst consensus (58% buy ratings) support upside, but legal risks and recent earnings misses pose significant headwinds. Investors should weigh solid financials against litigation overhang and market sentiment pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →
